

Palliative treatment of chronic breathlessness syndrome: the need for P5 medicine

Authors:

Daisy J.A. Janssen^{1,2}, Miriam J. Johnson³.

Affiliations:

¹ Department of Research & Development, CIRO, Centre of expertise for chronic organ failure, Horn, The Netherlands;

² Department of Health Services Research, CAPHRI School for Public Health and Primary Care, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands;

³ Wolfson Palliative Care Research Centre, University of Hull, Hull, UK

Author of correspondence:

Daisy J.A. Janssen, MD PhD

Department of Research and Development

CIRO

Hornerheide 1, 6085 NM Horn, The Netherlands

T +31 475 587 686; E daisyjanssen@ciro-horn.nl

Word count: 1110

References: 22

To the editor,

Breathlessness is the most frequently reported symptom by patients with advanced chronic lung disease or chronic heart failure and has widespread consequences.[1] Despite optimal treatment for the underlying disease, disabling breathlessness persists for many – recently named chronic breathlessness syndrome.[2] Patients, and their families, may live with chronic breathlessness for years, with serious functional and social limitations, care dependency and anxiety.[3] Clinical practice guidelines and policy statements now highlight pharmacological and non-pharmacological interventions for the palliative management of breathlessness as a cornerstone of care.[4,5] Despite this, many clinicians still feel ill-equipped and under-resourced to manage breathlessness, which remains a neglected symptom.[1,6]

Although the evidence base for breathlessness interventions is growing, important questions concerning optimal palliative management of breathlessness remain.[7] Studies of opioids are mostly small and of cross-over design. The most recent Cochrane review[8] found a smaller effect size and lower precision than other authors, although a repeat analysis[9] of the same studies accounting for the cross-over design of most showed a larger effect size with improved precision and benefit consistent with a clinically relevant improvement.[10] Safety concerns appear unfounded with oral low dose opioid. Indeed, national cohorts of oxygen-dependent COPD and advanced ILD found no association with excess hospital admission or mortality.[11,12] Another very large cohort of people with COPD showed a statistically significant, small absolute excess mortality but data regarding reason for prescribing (e.g. pain or breathlessness) was not available making clinical interpretation difficult.[13] A systematic review found no evidence for clinically relevant respiratory adverse effects.[14]

In this issue, Currow and colleagues[15] describe the results of the first, large, parallel group trial studying efficacy and safety of one-week's treatment with daily 20mg oral sustained-release morphine compared with placebo for chronic breathlessness. They recruited 284 participants in 14 inpatient and outpatient cardiorespiratory and palliative care services in Australia. In contrast to the earlier positive results, they found no differences in the primary (breathlessness "now") or secondary breathlessness scores ("worst/past 24 hours"; "average/past 24 hours"; "unpleasantness") between the study arms after one week of treatment. Health-related quality of life was comparable between groups. Of note, there was no between group statistical difference in adverse events, although constipation, nausea, fatigue and study-drug withdrawal were higher in the intervention group. Respiratory depression was not seen.

This well-conducted trial adds significantly to the available knowledge concerning morphine for breathlessness. It confirmed that low-dose morphine is well tolerated in this population, but raises the question of why they didn't confirm previous positive findings. The authors discuss two limitations which might have contributed to the lack of effect. *First*, Currow et al.[15] screened 1141 people for their study and managed to include 167 participants with mMRC grade 3 or 4. The eligibility criteria were expanded during the study to include people with mMRC 2 breathlessness in order to achieve their required sample size. An individual pooled data analysis of opioid trials showed that patients with less severe breathlessness were less likely to benefit[16] and it is notable that this trial's subgroup analysis (baseline mMRC 3 or 4), was insufficiently powered to discard the null hypothesis, showed a benefit trend for 'worst breathlessness' and 'unpleasantness' measures of breathlessness. *Second*, the ethics committee required that participants in both groups were allowed oral morphine solution as rescue medication. The placebo group used more rescue morphine, although both groups used low dosages and the difference was small. Nevertheless, this may have contributed to the lack of effect.

So, how to go from here? Should we put aside previous laboratory and clinical study evidence and conclude that the currently recommended pharmacological palliation of breathlessness, opioids, is ineffective? We argue not, but we do need to rethink how we assess, treat and study breathlessness in palliative care.

Firstly, the bedrock of palliative breathlessness management remains non-pharmacological. This is prioritized in clinical recommendations such as the breathlessness "ladder"[5] where opioids are reserved for those with persistent severe breathlessness despite non-pharmacological approaches in keeping with known predictors of opioid benefit[10]. Given the multi-factorial genesis of breathlessness and its multi-component complex management, distinguishing additional benefit from opioids is challenging in those where the relative contribution to benefit may be less. Therefore, opioid studies should exclude people with less severe breathlessness, and other interventions received should be documented, not only to prevent dilution of benefit, but to reflect the likely clinical context for use.

Secondly, therefore, we need to consider carefully how best to define such a study population. As Currow and colleagues correctly point out, mMRC assesses functional limitations of breathlessness, rather than its intensity, and has a ceiling effect in people with advanced disease.[17] Future clinical and laboratory studies are needed to further improve our understanding of patients most likely to

respond to opioids. For example, recent fMRI evidence suggests that depression may attenuate breathlessness benefit from opioids.[18]

Thirdly, we need to rethink how we best measure patient-relevant breathlessness outcomes to evaluate the effect of interventions for chronic breathlessness. A uni-dimensional measure is unlikely to reflect full impact during daily life. The integral relationship between breathlessness and physical activity – with its own impact on function and quality of life – brings a further challenge.[19] Effective palliation will allow patients to be more physically active whilst experiencing the same intensity of breathlessness. The lack of physical activity measures in Currow et al does not allow us to interpret their findings in this light. Other candidates for meaningful outcome measurement should also be explored such as Ecological Momentary Assessment (EMA[20]) or Goal Attainment Scaling (GAS[21]). EMA involves repeated measurements of the patient’s symptoms (such as breathlessness), behaviour and context in real time. Combined with assessment of physical activity, this might allow a more “real-life” assessment of the effect of palliative treatments on breathlessness. GAS allows patients to set personalized rehabilitative goals.[21]

Meanwhile, chronic breathlessness remains burdensome for millions of patients globally. Attention for P4 medicine (predictive, preventive, personalized and incorporating patient participation) in chronic lung diseases such as COPD is increasing.[22] For effective treatment of such a complex syndrome as chronic breathlessness syndrome, we need P5 medicine (Palliative, Predictive, Preventive, Personalized and Participatory): Multicomponent *Palliative* interventions which can be selected and applied based on a *prediction* of a beneficial response; breathlessness assessment and palliative interventions which can *prevent* further suffering; *personalized* palliative interventions tailored to individual needs and preferences; and involving patients as active partners in these palliative interventions which allow patients to *participate* in all their desired aspects of daily life.

Currow and colleagues are to be congratulated in completing a challenging trial. The research community must build on such work, incorporating key lessons, to develop the evidence base to inform management for people living with this debilitating and neglected syndrome.

References

1. Hutchinson A, Barclay-Kingle N, Galvin K, et al. Living with breathlessness: a systematic literature review and qualitative synthesis. *Eur Respir J* 2018;51
2. Johnson MJ, Yorke J, Hansen-Flaschen J, et al. Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness. *Eur Respir J* 2017;49
3. Janssen DJ, Wouters EF, Spruit MA. Psychosocial consequences of living with breathlessness due to advanced disease. *Curr Opin Support Palliat Care* 2015;9:232-7.
4. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. *Am J Respir Crit Care Med* 2008;177:912-27.
5. Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. *Can Respir J* 2011;18:69-78.
6. Ahmadi Z, Sandberg J, Shannon-Honson A, et al. Is chronic breathlessness less recognised and treated compared with chronic pain? A case-based randomised controlled trial. *Eur Respir J* 2018;52
7. Currow DC, Abernethy AP, Allcroft P, et al. The need to research refractory breathlessness. *Eur Respir J* 2016;47:342-3.
8. Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. *Cochrane Database Syst Rev* 2016;3:CD011008.
9. Ekstrom M, Bajwah S, Bland JM, et al. One evidence base; three stories: do opioids relieve chronic breathlessness? *Thorax* 2018;73:88-90.
10. Johnson MJ, Bland JM, Oxberry SG, et al. Clinically important differences in the intensity of chronic refractory breathlessness. *J Pain Symptom Manage* 2013;46:957-63.
11. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. *BMJ* 2014;348:g445.
12. Bajwah S, Davies JM, Tanash H, et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. *Eur Respir J* 2018;52
13. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use and adverse respiratory outcomes among older adults with COPD. *Eur Respir J* 2016;48:683-93.
14. Verberkt CA, van den Beuken-van Everdingen MHJ, Schols J, et al. Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis. *Eur Respir J* 2017;50
15. Currow D, Louw S, McCloud P, et al. Regular, Sustained Release Morphine for Chronic Breathlessness: A Multi-centre, Double-blind, Randomised, Placebo Controlled Trial. *Thorax* 2019;(epub ahead of print)
16. Johnson MJ, Bland JM, Oxberry SG, et al. Opioids for chronic refractory breathlessness: patient predictors of beneficial response. *Eur Respir J* 2013;42:758-66.
17. Sandberg J, Johnson MJ, Currow DC, et al. Validation of the Dyspnea Exertion Scale of Breathlessness in People With Life-Limiting Illness. *J Pain Symptom Manage* 2018;56:430-35 e2.
18. Pattinson KT, Johnson MJ. Neuroimaging of central breathlessness mechanisms. *Curr Opin Support Palliat Care* 2014;8:225-33.
19. Ekstrom M. Why treatment efficacy on breathlessness in laboratory but not daily life trials? The importance of standardized exertion. *Curr Opin Support Palliat Care* 2019;13:179-83.
20. Maes IH, Delespaul PA, Peters ML, et al. Measuring health-related quality of life by experiences: the experience sampling method. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research* 2015;18:44-51.
21. Krasny-Pacini A, Hiebel J, Pauly F, et al. Goal attainment scaling in rehabilitation: a literature-based update. *Ann Phys Rehabil Med* 2013;56:212-30.

22. Franssen FM, Alter P, Bar N, et al. Personalized medicine for patients with COPD: where are we?
Int J Chron Obstruct Pulmon Dis 2019;14:1465-84.

Exclusive license

D.J.A. Janssen, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in Thorax and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Disclosures

Dr. Janssen reports personal fees from Boehringer Ingelheim, personal fees from Novartis, and personal fees from AstraZeneca, outside the submitted work.

Dr. Johnson is clinical consultant for Mayne Pharma for which the University of Hull received payment.

Author contributions

Both authors had substantial contributions to the conception or design of the work; drafting the work and revising it critically for important intellectual content; final approval of the version published. Both authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.